|
More Effective Treatment for Colorectal Metastases to the Liver
Untitled Document
Name of the Trial
Phase II Study of Isolated Hepatic Perfusion With Melphalan in Patients With
Unresectable Colorectal Cancer Metastatic to the Liver and Refractory to First-Line
Systemic Chemotherapy (NCI-04-C-0229). See the protocol
summary 3.
Principal Investigator
 |
Dr. H. Richard Alexander
Principal Investigator |
Dr. H. Richard Alexander, NCI Center for Cancer Research.
Why This Trial Is Important
More than 145,000 people in the United States will be diagnosed with colorectal
cancer this year, making it the third most common cancer in the United States. Approximately
half of diagnosed patients will suffer from advanced disease that has spread
(metastasized) to other parts of the body, most commonly to the liver. Nearly
70 percent of the deaths attributed to colorectal cancer occur in patients who
have liver metastases.
Many metastatic colorectal tumors in the liver cannot be removed surgically
and often respond to systemic combination
chemotherapy for only a short time.
In this phase II study, researchers are using a surgical procedure known as isolated hepatic perfusion (IHP) to deliver melphalan, an anticancer drug,
directly to the liver while avoiding unnecessary systemic toxicity. Melphalan causes
significant regression of metastatic tumors in the liver when given at very
high doses, an effect that can help extend the lives of some patients for many
months. Isolated perfusion was developed to confine drugs such as melphalan
to a target organ or limb, thus sparing normal tissues from toxic effects.
"We can think of IHP as a physical method of targeting relatively nonspecific
anticancer drugs to the sites of metastatic disease," said Dr. Alexander.
"Because it is a one-time therapy with notable antitumor activity, we hope
it will substantially improve the quality of life of patients with refractory
advanced colorectal cancer."
Contact Information
This clinical trial is no longer accepting patients. To locate other clinical trials for colorectal cancer, search the NCI's database of clinical trials 1 or call the NCI Clinical Trials Referral Office at 1-888-NCI-1937.
The toll-free call is confidential.
|